Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18963298 | 1.00 | HCRTR2 (0.41) | HCRTR2TERTFFAR1LTB4RLTB4R2 | |
| SCHEMBL12355153 | 0.78 | DRD2 (0.40) | HCRTR2FFAR1CA2 | |
| SCHEMBL17107533 | 0.73 | HCRTR2 (0.42) | HCRTR2TERT | |
| SCHEMBL758865 | 0.71 | PNMT (0.47) | HCRTR2TERTCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL19199575 | 0.71 | HCRTR2 (0.44) | HCRTR2TERTFFAR1CHRNB2CHRNA4 | |
| SCHEMBL909508 | 0.70 | HTT (0.46) | FFAR1CTNNB1WNT3ACA2 | |
| SCHEMBL21810954 | 0.70 | HCRTR2 (0.43) | HCRTR2TERTFFAR1LTB4RLTB4R2 | |
| SCHEMBL909799 | 0.70 | HTT (0.46) | FFAR1CTNNB1WNT3ACA1CA2 | |
| SCHEMBL909506 | 0.70 | HTT (0.46) | FFAR1CTNNB1WNT3ACA2 | |
| SCHEMBL909948 | 0.70 | HTT (0.46) | FFAR1CTNNB1WNT3ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166566-A1 | SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PFIZER (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166566-A1 | SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PFIZER (US) | 2017-06-15 | — | — | US | disclosed |
| WO-2015150957-A1 | CHROMENE AND 1,1 A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150274721-A1 | NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES | PFIZER (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150274721-A1 | NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES | PFIZER (US) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274721-A1 | NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES | CYP4B1, CTRB1, CTRB2 | HCRTR2 1434/4885TERT 1127/4885FFAR1 1674/4885 |
| US-20170166566-A1 | SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PRNP, MAOB | HCRTR2 1691/4885TERT 1445/4885FFAR1 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.